EL7.AI
StocksMedium•17 November 2026•
1 min read

EC Approves Ionis Pharmaceuticals' TRYNGOLZA for Severe Hypertriglyceridemia

Key Facts

1The European Commission authorized TRYNGOLZA (olezarsen) as an adjunct therapy for adult patients with severe hypertriglyceridemia.

The European Commission authorized TRYNGOLZA (olezarsen) as an adjunct therapy for adult patients with severe hypertriglyceridemia. Benzinga reported that the marketing authorization allows the drug to be used alongside diet and other lipid-lowering therapies to manage patient lipid levels.

The regulatory approval follows clinical assessments of the drug's efficacy in managing lipid levels in patients suffering from severe hypertriglyceridemia. This milestone for Ionis Pharmaceuticals expands its therapeutic reach within the European Union market for metabolic disorders.

Open on chart